Results 171 to 180 of about 404,735 (263)

Assessing the risk of low energy availability, bone mineral density and psychological strain in endurance athletes. [PDF]

open access: yesJ Int Soc Sports Nutr
Gowers CR   +5 more
europepmc   +1 more source

Association of visceral fat metabolic score with bone mineral density and osteoporosis: a NHANES cross-sectional study. [PDF]

open access: yesJ Health Popul Nutr
Gu P   +9 more
europepmc   +1 more source

Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin   +11 more
wiley   +1 more source

Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation

open access: yesArthritis &Rheumatology, EarlyView.
Objective Chondrocytemetabolic dysfunction plays an important role in osteoarthritis (OA) development during aging and obesity. Protein posttranslational modifications (PTMs) have recently emerged as an important regulator of cellular metabolism. We aim to study one type of PTM, lysine malonylation (MaK), and its regulator sirtuin 5 (Sirt5) in OA ...
Huanhuan Liu   +11 more
wiley   +1 more source

Association of triglyceride-glucose index with bone mineral density and fracture: a systematic review. [PDF]

open access: yesDiabetol Metab Syndr
Yousefiasl M   +8 more
europepmc   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis

open access: yesArthritis &Rheumatology, Accepted Article.
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Home - About - Disclaimer - Privacy